Eton Pharmaceuticals (ETON) said Friday it completed the asset purchase deal to acquire Increlex from Ipsen.
Increlex, a biologic indicated for the treatment of patients 2 years to 18 years of age with severe primary insulin-like growth factor 1 deficiency, will now be available in the US exclusively through AnovoRx, according to the company.
Ipsen will continue to distribute Increlex outside the US for a six-month transition period and after that Eton will take over commercialization, Eton added.
Financial terms of the asset purchase agreement were not disclosed.
Shares of Eton were up 3.7% in recent trading.
Price: 12.73, Change: +0.45, Percent Change: +3.66
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.